<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>House of Commons Science and Technology Committee</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">AstraZeneca</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0018)</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Executive summary</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca welcomes the renewed focus on antimicrobial resistance. The issues are complex, and a multi-agency, multi-faceted approach is needed. The Government’s recent Five Year Strategy is a step in the right direction, but greater clarity is needed on implementation. It is vital that the pharmaceutical industry is involved at the heart of these discussions.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are two key issues that need to be addressed: reducing the speed of (inevitable) resistance to existing antibiotics and the development of a robust pipeline of new drugs.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Although the UK is widely renowned for its world-leading antibiotic stewardship, there are still some practices that are driving poor prescribing behaviour and leading to perverse outcomes. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">While the current healthcare associated infections (HCAIs) targets for MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">have been superficially successful, they have had a number of unintended consequences, including a worrying reduction in antibiotic diversity and an increase in the use of and resistance to critically important last-line antibiotics. HCAI targets should be reviewed, and disproportionate financial penalties removed, in order to ensure appropriate antibiotic use within the NHS.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are considerable barriers that disincentivise investment in the development of new antibiotics. Not only are the healthcare benefits of antibiotics undervalued by healthcare systems and wider society, they also deliver a poor return on investment when compared to other therapy areas.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is an urgent need to implement alternative funding models in order to revitalise the antibiotic pipeline. There are a number of measures that could be considered, including a licence fee model, which would deliver a market-based solution that incentivises and rewards innovation, provides a long term solution to enable us to stay ahead of continuing and growing resistance, and retains scientific talent.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">About AstraZeneca</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca is a UK-based, innovation-driven global biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> In the UK, AstraZeneca employs around 7,000 people, including 3,000 scientists, working collaboratively with our external stakeholders to seek out the best science, deliver innovative new medicines, improve health outcomes for patients and deliver maximum value to the NHS. </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca contributes significantly to the UK economy, investing around £1 billion annually in R&amp;D associated with our UK operations, and accounting for around 2% of the total UK export of goods. AstraZeneca has a long heritage in antibiotics and we are one of the few European companies with an active antibiotic pipeline.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Terms of Reference</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca believes there is no substitute to talking to experts in this area and would suggest opinion is sought from national advisors and experts in antimicrobial resistance (AMR) and healthcare associated infections (HCAIs) such as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium difficile (C. difficile)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR is an inevitable consequence of using antibiotics, and therefore we need a long-term, sustainable plan.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca supports a group of </span><span style="font-family:'Times New Roman'; font-size:11pt">leading clinical and academic experts</span><span style="font-family:'Times New Roman'; font-size:11pt"> who are looking at how we can improve prescribing practice in our hospitals to reduce the short-term threat of AMR and suggest </span><span style="font-family:'Times New Roman'; font-size:11pt">practical recommendations.</span><span style="font-family:'Times New Roman'; font-size:11pt"> They report there is an important correlation between volume of prescribing and resistance rates, but that current data collection on antibiotic prescribing and its relation to infection incidence is inadequate. Existing data does not allow for hospital comparisons and is not always reliable.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is a need to ensure a robust pipeline of new antibiotics.</span><a name="_ednref1"></a><a href="#_edn1">[1]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This is increasingly difficult. Half of the antibiotics used today were discovered during the 1950s, while the last new class of antibiotics was discovered over 25 years ago.</span><a name="_ednref2"></a><a href="#_edn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt"> Many pharmaceutical companies have closed their antibiotic R&amp;D departments: in 1990, there were 18 large companies actively involved in antimicrobial R&amp;D;</span><a name="_ednref3"></a><a href="#_edn3">[3]</a><span style="font-family:'Times New Roman'; font-size:11pt"> by 2013 there were only four.</span><a name="_ednref4"></a><a href="#_edn4">[4]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">When it comes to antibiotics, the current incentives for pharmaceutical innovation are not working, despite the expectation that industry needs to drive the development of new drugs.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1 </span><span style="font-family:'Times New Roman'; font-size:11pt">This is a challenge that we are prepared to meet, but there are considerable barriers that disincentivise investment in antibiotics. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">When making investment decisions, the industry considers the drug’s expected net present value (eNPV) – their potential return on investment (ROI). Areas such as oncology and musculoskeletal conditions can deliver an eNPV three to five times that of antibiotics (see graph below).  Unsurprisingly, a much larger number of new drugs in these therapy areas have come to market in recent years compared to antibiotics,</span><a name="_ednref5"></a><a href="#_edn5">[5]</a><span style="font-family:'Times New Roman'; font-size:11pt"> and without a change to the incentives for R&amp;D investment in new antibiotics this is a trend that is likely to continue.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><img src="data:image/png;base64,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" width="480" height="360" alt="" style="float:left; margin:0pt 9pt" /></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotic eNPV is low for a number of reasons. Treatment durations are normally much shorter than other chronic therapies, while uptake is often hindered by attempts to maintain their efficacy. Antibiotics typically reach peak sales after 13 years, compared to just six for other drugs, by which time, they are no longer covered by the initial patent and so the company can struggle to recoup their investment. The issue is further compounded by the inherent difficulty associated with predicting how resistant bacteria will evolve and spread.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The process for assessing the value of antibiotics is another challenge. In our experience, the bodies responsible for reviewing new drugs, such as NICE and the Scottish Medicines Consortium, will only assess them as cost-effective if it is proved that they offer a significant improvement over existing alternatives. However, ethical considerations mean it is virtually impossible to conduct superiority trials for new antibiotics – or even to recruit enough appropriate patients into clinical trials.  This means the prices for most new antibiotics are unfavourable compared to the price of generic drugs, which further depresses ROI.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotics have been taken for granted for decades, and they are considerably undervalued when compared to medicines in other therapy areas. A recent BMJ paper by Smith and Coast concluded that the true cost of resistance is likely to be much higher than even the highest estimates currently available, especially if, in the near future, everyday surgeries such as hip operations became impossible due to the risk of a patient contracting an untreatable infection</span><a name="_ednref6"></a><a href="#_edn6">[6]</a><span style="font-family:'Times New Roman'; font-size:11pt"> – a view echoed by the Chief Medical Officer, Professor Dame Sally Davies.</span><a name="_ednref7"></a><a href="#_edn7">[7]</a></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AstraZeneca is involved in a number of workstreams to help understand what a </span><span style="font-family:'Times New Roman'; font-size:11pt">sustainable model to secure long-term antibiotic development might look like. We are involved with</span><span style="font-family:'Times New Roman'; font-size:11pt"> the EU Commission’s </span><span style="font-family:'Times New Roman'; font-size:11pt">Innovative Medicines Initiative</span><span style="font-family:'Times New Roman'; font-size:11pt"> New Drugs for Bad Bugs programme, in particular topic 4, ‘</span><span style="font-family:'Times New Roman'; font-size:11pt">Driving Re-Investment in R&amp;D and Responsible Use of Antibiotics</span><span style="font-family:'Times New Roman'; font-size:11pt">’.</span><a name="_ednref8"></a><a href="#_edn8">[8]</a><span style="font-family:'Times New Roman'; font-size:11pt"> We have also commissioned the </span><span style="font-family:'Times New Roman'; font-size:11pt">Office for Health Economics to look at a range of potential methods of incentivising antibiotic development. Models such as public-private partnerships,</span><span style="color:#c00000; font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt">which presently have a high public profile in the USA and Europe,</span><span style="font-family:'Times New Roman'; font-size:11pt"> could play an important role in supporting the development of new drugs. However, we feel they can only be one part of the solution. Any successful model to revitalise the industry’s pipeline of antibiotic drugs must be a market-based solution that incentivises and rewards innovation and provides a long term solution to enable us to stay ahead of continuing and growing resistance.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">One final area that we feel needs further consideration, at both a national and international level, is the role of environmental factors in spreading AMR. We are aware that many antibiotics can be found in the environment (largely through patient use, but also through manufacture, aquaculture and veterinary use) at concentrations that will lead to the development of resistance. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What measures (including behavioural change) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">NHS MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">targets, in conjunction with other measures, have proven very successful in their initial aim of lowering these specific infection rates,</span><a name="_ednref9"></a><a href="#_edn9">[9]</a><span style="font-family:'Times New Roman'; font-size:11pt"> but they have also had a number of unintended consequences. AstraZeneca agrees with others, including the CMO, that it is time to look beyond the current healthcare associated infections (HCAI) targets.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A narrow focus on just two HCAIs has meant that other infections, such as Gram-negative infections are not tackled with equal vigour. A typical 1000-bed acute NHS hospital now has two or three MRSA bacteraemias and 50-60 cases of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">a year, but 400-500 Gram-negative bacteraemias. Gram-negative bacteraemias have increased year on year and attributable mortality </span><span style="font-family:'Times New Roman'; font-size:11pt">greatly exceeds current mortality due to MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> difficile</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">, </span><span style="font-family:'Times New Roman'; font-size:11pt">accounting for nearly 5,000 deaths a year and an increased burden of additional care and cost.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This narrow focus on MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">has been the reduction in the regular use of some classes of antibiotics in a hospital setting. A significant risk factor for MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">in hospitals is poor implementation of infection control policies. All antibiotics can carry a risk of triggering a </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">infection in a susceptible patient. However, some commonly used broad spectrum antibiotics, such as cephalosporins and quinolones, are perceived to carry a slightly higher risk of this happening. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As a result, there has been a considerable drop in the use of these classes of antibiotics since the targets were introduced in 2007. Specialist clinicians fear using them, even in the most appropriate patients, as any resulting cases of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> could trigger large, disproportionate financial penalties. This is despite the fact that poor implementation of infection control policies is a more significant risk factor for MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile </span><span style="font-family:'Times New Roman'; font-size:11pt">in hospitals.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This unwillingness to use entire classes of antibiotics has in turn led to an increased reliance on other, critically important drugs such as piperacillin/tazobactam and carbapenems.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> In turn, we are starting to see a worrying increase in resistance to these vital drugs.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The reluctance to use whole classes of antibiotics has impacted on the industry’s ability to develop new drugs in the UK. AstraZeneca recently attempted to undertake clinical trials of a new cephalosporin in the UK (focussing on emerging resistant bacteria), but half of the trial centres approached refused to participate, specifically due to the fear of the potential financial penalties if C. difficile targets were breached.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR is a complex issue, and needs a multi-faceted, multi-agency approach if it is to be tackled successfully. As the Department of Health’s recent five-year AMR strategy noted, whilst it is important to ensure the efficacy of existing antibiotics is maintained for as long as possible, there is also a very real need to ensure a robust pipeline of new drugs to target infections as they develop resistance.</span><a name="_ednref10"></a><a href="#_edn10">[10]</a></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The global threat posed by AMR has been widely acknowledged in recent months, on both a national and international level, and it has been recognised that action needs to be taken to accelerate the discovery and development of new drugs to ensure a secure antibiotic pipeline.</span><a name="_ednref11"></a><a href="#_edn11">[11]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ednref12"></a><a href="#_edn12">[12]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ednref13"></a><a href="#_edn13">[13]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ednref14"></a><a href="#_edn14">[14]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><a name="_ednref15"></a><a href="#_edn15">[15]</a><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The US has implemented legislation to incentivise the development of new antibiotics with the Generating Antibiotic Incentives Now (GAIN) Act of 2011. The GAIN Act makes antibiotics eligible for priority review and fast-track approval from the Food and Drug Administration and also extends the patent of so-called ‘qualified infectious disease products’ – i.e. antibiotics that treat infections designated as a high priority by the Secretary of Health and Human Services.</span><a name="_ednref16"></a><a href="#_edn16">[16]</a></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK needs to make sure that we learn from international best practice and look to implement successful measures used elsewhere, as well as pioneer innovations that can be replicated on a global scale. The UK has a strong record when it comes to antimicrobial stewardship and we need to build momentum with other like-minded nations, such as Sweden and the US, to deliver long term solutions to ensure we stay one step ahead of AMR.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We welcomed the publication of the UK Five Year Antimicrobial Resistance Strategy. There is clear recognition of the need for industry to work to extend the life of existing antimicrobials and develop new ones, as well as diagnostics. Assessment of the challenges facing pharmaceutical companies in the quest to find new antibiotics has improved but remains incomplete. </span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="30" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We welcome the intent behind the strategy, but much greater clarity on implementation is necessary: we need to know what will now change as a result. The strategy needs to be joined up with other initiatives, including those aimed at reducing HCAIs.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="31" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">AMR cannot be tackled in isolation, and industry will have a key role to play in meeting the challenge. We want t</span><span style="font-family:'Times New Roman'; font-size:11pt">o play our part, and we are already working with multiple stakeholders in order to achieve this; we will need to remain at the heart of discussions.</span></li></ol><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Recommendations for action</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="32" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As referenced in paragraph 10, AstraZeneca is working with a </span><span style="font-family:'Times New Roman'; font-size:11pt">group of clinical experts</span><span style="font-family:'Times New Roman'; font-size:11pt"> in this field.  These experts </span><span style="font-family:'Times New Roman'; font-size:11pt">believe there is a need to improve the utility of data available to the NHS and clinicians, to improve understanding of current antibiotic prescribing practice with clearer links to patient outcomes. They also feel that changing the focus of the current HCAI targets would improve patient care, and recommend the implementation of three measures to drive high quality antibiotic prescribing, improve patient outcomes and protect the efficacy of existing antibiotics.  The measures are:</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="33" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">a) Improved data collection through electronic prescribing, accompanied by data analysis, with clear links to patient outcomes. </span><span style="font-family:'Times New Roman'; font-size:11pt">New ways to monitor antibiotic use must be developed, which should record the amounts and types of antibiotics used, and measure both the appropriateness and diversity of prescribing and associated antimicrobial resistance.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="34" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">b) Broaden the focus of HCAI improvement objectives to include other significant infections, such as Gram-negative infections and urinary or intravascular catheter infections, with a greater focus on multi-drug resistant infections, especially those resistant to critical antibiotics. </span><span style="font-family:'Times New Roman'; font-size:11pt">Rather than maintain a narrow focus on MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C. difficile,</span><span style="font-family:'Times New Roman'; font-size:11pt"> a broader composite HCAI objective would give a more accurate measurement of avoidable HCAIs.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="35" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">c) Rationalise the penalties for breaches of HCAI targets.  </span><span style="font-family:'Times New Roman'; font-size:11pt">In place of the current large fines for missing HCAI objectives/targets, incentives should be considered to encourage high quality antibiotic prescribing and HCAI outcomes.  Hospitals should be required to publish their HCAI rates in standard, easy to understand way.  This kind of open data reporting would enable patients and referring GPs to make informed choices.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="36" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We have commissioned the Office of Health Economics to investigate potential solutions for the broken commercial model for antibiotics, including license fees; patent life extension; public-private partnerships; and simply charging a higher price. It is highly unlikely that there is one single solution to this complex area, but two clear areas have emerged where we recommend further discussion and focus:</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="37" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">a) Ensure funding is considered at national, rather than local level</span><span style="font-family:'Times New Roman'; font-size:11pt">. Funding for a market based solution would be more appropriate at a national or supra-national level. This would mean the burden of antibiotic resistance is not placed on individual hospitals or communities as and when they suffer an outbreak – as befits the view that AMR is a national risk on a par with </span><span style="font-family:'Times New Roman'; font-size:11pt">terrorism or other external risks.</span><a name="_ednref17"></a><a href="#_edn17">[17]</a><span style="font-family:'Times New Roman'; font-size:11pt"> The other benefit of such a national funding model is that it would allow prescribers to focus on using the most appropriate antibiotic rather than the one that is the cheapest, thereby supporting antimicrobial stewardship and a greater diversity of antibiotic use.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="38" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">b) Consider a license fee model for funding future antibiotics.  </span><span style="font-family:'Times New Roman'; font-size:11pt">This would guarantee access to qualifying antibiotics for a fixed five year fee. The benefits of such a scheme would be:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">removal of local budget pressures, ensuring that prescribing decisions could be made purely on the appropriate clinical use of a new antibiotic</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a manageable and predictable impact on healthcare expenditure</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">incentivises research into antibiotics to treat rarer resistant pathogens, which could become the major causes of bacterial diseases in the future.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">enables a more appropriate way to assess the value a new antibiotic brings to the healthcare system</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a significant impact on company eNPVs as revenues would be brought forward in the lifetime of a new drug</span></li></ul><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="39" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are multiple stakeholders involved in decision-making: any commercial model needs to ensure the healthcare system continues to pay a fair value for new drugs. A market-based solution will address the short term problem of a lack of new antibiotics, and will also attract investment back into the area to make sure we stay one step ahead of AMR; as AMR will be ever-present, we need to continually innovate in this area.</span></li></ol><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">REFERENCES</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_edn1"></a><a href="#_ednref1">[1]</a><span style="font-family:Arial; font-size:8pt">Annual Report of the Chief Medical Officer Volume Two, 2011. Infections and the rise of antimicrobial resistance. Available at: </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf</span></a><span style="font-family:Arial; font-size:8pt">. Accessed September 2013</span></p><p style="margin:0pt"><a name="_edn2"></a><a href="#_ednref2">[2]</a><span style="font-family:Arial; font-size:8pt"> World Health Organization Regional Office for Europe. Self-prescription of antibiotics boosts superbugs epidemic in the European Region. November 16, 2012. Available at: </span><a href="http://www.euro.who.int/en/what-we-publish/information-for-the-media/sections/latest-press-releases/self-prescription-of-antibiotics-boosts-superbugs-epidemic-in-the-european-region"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.euro.who.int/en/what-we-publish/information-for-the-media/sections/latest-press-releases/self-prescription-of-antibiotics-boosts-superbugs-epidemic-in-the-european-region</span></a><span style="font-family:Arial; font-size:8pt">. Accessed September 2013</span></p><p style="margin:0pt"><a name="_edn3"></a><a href="#_ednref3">[3]</a><span style="font-family:Arial; font-size:8pt"> Office of Health Economics. New drugs to tackle antimicrobial resistance: analysis of EU policy options. April 2011. Available for download from: </span><a href="http://www.ohe.org/page/index.cfm"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.ohe.org/page/index.cfm</span></a><span style="font-family:Arial; font-size:8pt">. Accessed September, 2013</span></p><p style="margin:0pt"><a name="_edn4"></a><a href="#_ednref4">[4]</a><span style="font-family:Arial; font-size:8pt"> Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating Antimicrobial Resistance: Policy Recommendations To Save Lives. Clin Infect Dis 2011:52(Suppl 5):S397-428</span></p><p style="margin:0pt"><a name="_edn5"></a><a href="#_ednref5">[5]</a><span style="font-family:Arial; font-size:8pt"> Projan S. (2003) Why big pharma is getting out of AB discovery, Current Opinion in Microbiology 2003, 6:427-430</span></p><p style="margin:0pt"><a name="_edn6"></a><a href="#_ednref6">[6]</a><span style="font-family:Arial; font-size:8pt"> Smith R and Coast J, The true cost of antimicrobial resistance, British Medical Journal 2013;346</span><br /><a href="http://www.bmj.com/content/346/bmj.f1493"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.bmj.com/content/346/bmj.f1493</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn7"></a><a href="#_ednref7">[7]</a><span style="font-family:Arial; font-size:8pt"> Sally Davies, The drugs don’t work, Sunday Times, 15 September 2013</span></p><p style="margin:0pt"><a href="http://www.thesundaytimes.co.uk/sto/newsreview/features/article1313446.ece"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.thesundaytimes.co.uk/sto/newsreview/features/article1313446.ece</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn8"></a><a href="#_ednref8">[8]</a><span style="font-family:Arial; font-size:8pt"> Innovative</span><span style="font-family:Arial; font-size:8pt"> Medicines Initiative, </span><span style="font-family:Arial; font-size:8pt">9th Call for Proposals 2013</span><span style="font-family:Arial; font-size:8pt">, July 2013. </span><a href="http://www.imi.europa.eu/webfm_send/914"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.imi.europa.eu/webfm_send/914</span></a></p><p style="margin:0pt"><a name="_edn9"></a><a href="#_ednref9">[9]</a><span style="font-family:Arial; font-size:8pt"> Health Protection Agency, Healthcare-Associated Infection and Antimicrobial Resistance: 2010-2011, August 2012 </span><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn10"></a><a href="#_ednref10">[10]</a><span style="font-family:Arial; font-size:8pt"> Department of Health, UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, 10 September 2013. Available at </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf</span></a></p><p style="margin:0pt"><a name="_edn11"></a><a href="#_ednref11">[11]</a><span style="font-family:Arial; font-size:8pt"> House of Commons Science and Technology Committee,  Uncorrected Transcript Of Oral Evidence from the Chief Medical Officer, Department of Health, HC 921-I, Published 11</span><span style="font-family:Arial; font-size:5.33pt; vertical-align:super">th</span><span style="font-family:Arial; font-size:8pt"> February 2013</span></p><p style="margin:0pt"><a href="http://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn12"></a><a href="#_ednref12">[12]</a><span style="font-family:Arial; font-size:8pt"> World Health Organisation. World Health Day 2011: Urgent action necessary to safeguard drug treatments. News Release. 06 April 2011 </span><a href="http://www.who.int/mediacentre/news/releases/2011/whd_20110406/en/index.html"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.who.int/mediacentre/news/releases/2011/whd_20110406/en/index.html</span></a></p><p style="margin:0pt"><a name="_edn13"></a><a href="#_ednref13">[13]</a><span style="font-family:Arial; font-size:8pt"> World Economic Forum, Global Risks 2013: Eighth Edition. Published 2013. Available at </span><a href="http://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/</span></a><span style="font-family:Arial; font-size:8pt"> Accessed September 2013</span></p><p style="margin:0pt"><a name="_edn14"></a><a href="#_ednref14">[14]</a><span style="font-family:Arial; font-size:8pt"> Infectious Diseases Society of America, The 10 x 20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020, Clin Infect Dis. (2010) 50 (8): 1081-1083</span></p><p style="margin:0pt"><a href="http://cid.oxfordjournals.org/content/50/8/1081.full.pdf+html"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://cid.oxfordjournals.org/content/50/8/1081.full.pdf+html</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn15"></a><a href="#_ednref15">[15]</a><span style="font-family:Arial; font-size:8pt"> Elaine A Irving presentation, New Drugs for Bad Bugs – Regulatory aspects in Innovative Medicines Initiative projects, November 2010</span></p><p style="margin:0pt"><a href="http://www.efpia.eu/uploads/Modules/Documents/nd4bb_overview_jan_2013.pdf"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.efpia.eu/uploads/Modules/Documents/nd4bb_overview_jan_2013.pdf</span></a><span style="font-family:Arial; font-size:8pt"> </span></p><p style="margin:0pt"><a name="_edn16"></a><a href="#_ednref16">[16]</a><span style="font-family:Arial; font-size:8pt"> Pew Health Group, Fact sheet:  The Generating Antibiotic Incentives Now Act of 2011, 20 September 2011 </span><a href="http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf</span></a></p><p style="margin:0pt"><a name="_edn17"></a><a href="#_ednref17">[17]</a><span style="font-family:Arial; font-size:8pt"> BBC News Online, Antibiotics resistance 'as big a risk as terrorism' - medical chief, 11 March 2013</span><br /><a href="http://www.bbc.co.uk/news/health-21737844"><span style="color:#0000ff; font-family:Arial; font-size:8pt; text-decoration:underline">http://www.bbc.co.uk/news/health-21737844</span></a></p></body></html>